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Diabetic-Nephropathy Susceptibility
He et al., page 5
Type I diabetes mellitus (T1DM) results from the body’s
inability to produce sufﬁcient insulin and is typically
diagnosed in children (juvenile diabetes). Diabetes results
in high levels of blood sugar, which may lead to capillary
damage. Retinopathy and kidney damage (nephropathy)
are among the potential complications of T1DM.
Although diabetic nephropathy (DN) is the primary cause
of death in T1DM patients, only about 30% of T1DM
patients develop this condition. There is evidence of a
genetic component to the development of DN in T1DM;
however, the complication does not follow simple Mende-
lian rules of inheritance. He and colleagues use a multi-
stage association study of a region of chromosome 3q22
previously linked with DN in T1DM patients to identify
genetic factors that might inﬂuence the occurrence of
this condition. Finish, Icelandic, and British patients
with T1DM are divided into two groups: those with no
clinical sign of renal damage (1874 patients) and those
with end-stage renal disease (ESRD), determined by persis-
tent large amounts of albumine in the urine (macro-
albuminuria) and retinopathy (1822 patients). Initial
screening identiﬁes 27 associated SNPs in one Finish
cohort. Replication in the other populations ﬁnds sig-
niﬁcant association of the minor allele C of SNP
rs1866813 with DN (odds ratio ¼ 1.33). Although haplo-
type-block analysis reveals no stronger association, the
intergenic region containing rs1866813 is evolutionarily
conserved. These data suggest that rs1866813 might inﬂu-
ence one or a number of neighboring genes expressed
in the glomerulus of the kidney, including NCKI and
TMEM22.
Genome-wide Association in Alzheimer Disease
Beecham et al., page 35
Alzheimer Disease (AD) is a debilitating disorder character-
ized by dementia in older individuals. Although there is
evidence that genetic factors are involved in the develop-
ment of late-onset Alzheimer Disease (LOAD), researchers
have had a difﬁcult time identifying variants that
contribute to disease risk. Risk alleles in one gene, APOE,
have been consistently found to be strongly associatedTwith LOAD susceptibility, and the strength of the effect
of variants at this locus is strong enough to be picked up
with the use of linkage techniques. Other loci with such
large effects have not been found. Beecham et al. hope to
identify additional genetic factors that contribute to
LOAD risk by executing a large case-control genome-wide
association study. In the genome-wide analysis, one non-
APOE SNP on 12q13, rs11610206, is associated with
LOAD at a genome-wide level of signiﬁcance. This SNP,
which lies within a region previously linked to AD, is
also found to be signiﬁcantly associated in a replica-
tion analysis of an independent data set of cases and
controls. The authors then use imputation to compare
and combine the association results from their study
with those from another genome-wide analysis. Beecham
et al. hope that future work will establish the mechanism
behind the relationship between the associated loci and
LOAD risk.
GWAS for Mean Platelet Volume
Meisinger et al., page 66
The number of platelets circulating in the blood needs to
be carefully maintained to ensure a proper balance
between the body’s ability to effectively respond to
damage and an abnormally high level of clot formation
that can cause strokes or heart attacks. Although some of
the factors involved in this tight regulation are known,
much of the process remains to be elucidated, but there
is evidence that mean platelet volume (MPV) is under
genetic control. MPV is an important diagnostic measure,
because it can serve as an indicator for how well patients
will respond after a cardiovascular or cerebral event. Mei-
singer et al. report the results of their genome-wide associ-
ation study, in which they work to establish genetic vari-
ants that are associated with MPV. Their initial analysis is
performed in a large German group. Signiﬁcant associa-
tions are then examined further in three independent
replication data sets; one UK data set and two German
data sets. Of the three signiﬁcant associations that were
identiﬁed and replicated, a SNP in WDR66 is believed to
have the strongest effect. The authors follow up this result
by performing a denser search and identify additional
WDR66 variants that are associated with MPV in their
samples.1Science Editor, AJHG; 2Deputy Editor, AJHG
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ACAN Mutation in SEMD Aggrecan Type
Tompson et al., page 72
Spondylepimetaphyseal dysplasia (SEMD) encompasses a
group of skeletal disorders characterized by short stature
due to defective remodeling of the vertebra (spondyl) and
longbones, includingboth the epiphyses and themetaphy-
ses. Several different genetic mutations leading to alterna-
tive forms of SEMD have been identiﬁed in genes encoding
extracellular-matrix or matrix-remodeling proteins found
in cartilage. Aggrecan is the most abundant proteoglycan
of cartilage extracellular matrix, and recent genome-wide
studies have implicated ACAN as a regulator of height.
Additionally, amilddominant formof SEMD, termedSEMD
Kimberly type, was previously shown to be caused by a
frameshift mutation in ACAN. Here, the authors identify
a new form of SEMD characterized by extreme short stature
and unique radiographic ﬁndings, including clefts of the
cervical vertebral bodies and extra ossiﬁcation centers in
bones of the hands. Through homozygosity mapping,
Tompson et al. identify a candidate region containing 193
annotated genes. Using expression analysis, they narrow
the number of genes to only those expressed in cartilage
and subsequently identify a point mutation in ACAN
changing a conserved aspartic-acid residue. In addition to
altering a conserved amino acid, the homozygous recessive
mutation might create an additional glycosylation site on
the protein, altering its biological activity. Carrier parents
and siblings present with shorter stature than the sibling
lacking the mutation. The authors term this new auto-
somal-recessive disease ‘‘SEMD aggrecan type’’ and suggest
the possibility of a carrier phenotype.2 The American Journal of Human Genetics 84, 1–2, January 9, 2009FIG4 Mutations in ALS
Chow et al., page 85
Previous work in human and mouse has demonstrated
that disruption of FIG4 affects motor-neuron function.
The mouse model for deﬁciency of this phosphoinosi-
tide 5-phosphatase presents with severe neuron degen-
eration, and FIG4 mutations have been identiﬁed in
a severe form of Charcot-Marie-Tooth disease, CMT4J.
Here, Chow et al. predict that some cases of amyotro-
phic lateral sclerosis (ALS) and primary lateral sclerosis
(PLS) might also be caused by mutations in FIG4. ALS
and PLS are neurodegenerative diseases, of which little
is known about the genetic etiology. Only a small
percentage of the genetic etiology of ALS has been
determined, and no mutations have yet been linked
to PLS. To determine the role that disruption of FIG4
might play in ALS and PLS, the authors screen a large
patient data set consisting of both familial and sporadic
cases. A variety of variants are identiﬁed, including
truncation mutations, splice-site mutations and
missense mutations. The pathogenicity of the missense
alleles is tested through the use of a yeast rescue assay,
and the authors establish that two of the missense
mutations are likely to be disease causing. The authors
suggest that it is the involvement of phosphoinositides
in vesicle trafﬁcking that is affected. Disruption of
phosphoinositides has been linked to other motor-
neuron disorders, and the vesicle-trafﬁcking process is
thought to be important in these diseases because of
the high level of membrane turnover in motor
neurons.
